Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Aggression × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 10 Multiple Myeloma 6 Sarcoma 5 Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neurofibrosarcoma 2 Myelodysplastic Syndromes 2 Melanoma 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, Biphenotypic, Acute 2 Glioblastoma 2 Congenital Abnormalities 2 Colorectal Neoplasms 2 Central Nervous System Neoplasms 2 Waldenstrom Macroglobulinemia 1 Solid Tumors 1 Sarcoma, Ewing 1 Sarcoma, Endometrial Stromal 1 Sarcoma, Alveolar Soft Part 1 Rhabdoid Tumor 1 Recurrence 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1

Interventions

selinexor 1 Rituximab 1 Ifosfamide 1 Etoposide 1 Dexamethasone 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡